Key result
TAPSE/PASP ≤ 0.35 is linked to higher heart failure readmissions and mortality after MitraClip.
Why the study?
Heart failure readmissions and death remain substantial after transcatheter mitral valve repair for severe mitral regurgitation, and the prognostic value of TAPSE/PASP ratio as a non-invasive measure of RV-to-PA coupling in this population was unknown.
Does a lower TAPSE/PASP ratio (≤ 0.35) predict increased heart failure readmissions and all-cause mortality in patients undergoing TMVR with MitraClip?
Does a lower TAPSE/PASP ratio (≤ 0.35) predict increased heart failure readmissions and all-cause mortality in patients undergoing TMVR with MitraClip?
A TAPSE/PASP ratio ≤ 0.35 is a significant independent predictor of heart failure readmission and all-cause mortality in patients undergoing MitraClip implantation.
May refine post-MitraClip risk stratification; extends RV-PA coupling observations but remains hypothesis-generating.
Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. Recently, right ventricular (RV) to pulmonary arterial (PA) coupling has emerged as a relevant prognostic predictor in HF. In this study, we aimed to assess the prognostic value of tricuspid annular plane systolic excursion (TAPSE) to PA systolic pressure (PASP) ratio as a non-invasive measure of RV-to-PA coupling in patients undergoing TMVR with MitraClip (Abbott, CA, USA). Methods: Multicentre registry including 228 consecutive patients that underwent successful TMVR with MitraClip. The sample was divided in two groups according to TAPSE/PASP median value: 0.35. The primary combined endpoint encompassed HF readmissions and all-cause mortality. Results: Mean age was 72.5 ± 11.5 years and 154 (67.5%) patients were male. HF readmissions and all-cause mortality were more frequent in patients with TAPSE/PASP ≤ 0.35: Log-Rank 8.844, p = 0.003. On Cox regression, TAPSE/PASP emerged as a prognostic predictor of the primary combined endpoint, together with STS-Score. TAPSE/PASP was a better prognostic predictor than either TAPSE or PASP separately. Conclusions: TAPSE/PASP ratio appears as a novel prognostic predictor in patients undergoing MitraClip implantation that might improve risk stratification and candidate selection.
No takes yet. Share an insight, caveat, or question.
Trejo‐Velasco et al. (2021) studied this question. A TAPSE/PASP ratio ≤ 0.35 was associated with higher rates of heart failure readmissions and all-cause mortality in patients undergoing MitraClip therapy (Log-Rank 8.844, p = 0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: